drugset / Trial / NCT00158821

Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.

NCT00158821

Phase 3 Completed 180 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

To compare tenofovir DF plus lamivudine plus efavirenz vs. stavudine plus lamivudine plus efavirenz in the treatment of HIV-1-infected patients who have never taken antiretroviral drugs and have a viral load of less than 400 copies/mL at week 48.

Timeline

Start
2000-03
Primary completion
2001-12
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg
Background Efavirenz Other / unclassified 600 mg
Background Lamivudine Other / unclassified 150 mg